Mesoblast (ASX:MSB) has welcomed new research showing that its allogeneic cell therapy remestemcel-L delivers superior clinical outcomes compared with ruxolitinib for patients with steroid-refractory acute graft versus host disease. …
New analysis finds Mesoblast’s Remestemcel-L outperforms ruxolitinib in severe GvHD
December 14, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 15 May
May 15, 2026 - - Podcast -
New Zealand still falling behind on access to modern medicines
May 15, 2026 - - Latest News -
AusBiotech welcomes Budget's creation of new National Resilience and Science Council
May 15, 2026 - - Latest News -
Minister fired the starting gun in March, he flung the door open in Budget week
May 14, 2026 - - Latest News -
There are a number of reasons to criticise the minister on the PBS, but he is right to be annoyed about this
May 14, 2026 - - Latest News -
Long-term study finds continuing Mounjaro helps maintain weight loss
May 14, 2026 - - Latest News -
Frustrated minister encourages an early negotiation of new agreements
May 14, 2026 - - Latest News